CN113226283A - 通过操纵血浆重量摩尔渗透压浓度改善淋巴递送 - Google Patents

通过操纵血浆重量摩尔渗透压浓度改善淋巴递送 Download PDF

Info

Publication number
CN113226283A
CN113226283A CN201980075683.8A CN201980075683A CN113226283A CN 113226283 A CN113226283 A CN 113226283A CN 201980075683 A CN201980075683 A CN 201980075683A CN 113226283 A CN113226283 A CN 113226283A
Authority
CN
China
Prior art keywords
brain
antibody
composition
imaging
antagonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980075683.8A
Other languages
English (en)
Chinese (zh)
Inventor
M.内德加德
B.普洛格
H.梅斯特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Rochester
Original Assignee
University of Rochester
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Rochester filed Critical University of Rochester
Publication of CN113226283A publication Critical patent/CN113226283A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0058—Antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/0033—Features or image-related aspects of imaging apparatus, e.g. for MRI, optical tomography or impedance tomography apparatus; Arrangements of imaging apparatus in a room
    • A61B5/004—Features or image-related aspects of imaging apparatus, e.g. for MRI, optical tomography or impedance tomography apparatus; Arrangements of imaging apparatus in a room adapted for image acquisition of a particular organ or body part
    • A61B5/0042—Features or image-related aspects of imaging apparatus, e.g. for MRI, optical tomography or impedance tomography apparatus; Arrangements of imaging apparatus in a room adapted for image acquisition of a particular organ or body part for the brain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/0059—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence
    • A61B5/0077—Devices for viewing the surface of the body, e.g. camera, magnifying lens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0032—Methine dyes, e.g. cyanine dyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0056—Peptides, proteins, polyamino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Radiology & Medical Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medical Informatics (AREA)
  • Surgery (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Vascular Medicine (AREA)
  • Anesthesiology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
CN201980075683.8A 2018-10-04 2019-09-30 通过操纵血浆重量摩尔渗透压浓度改善淋巴递送 Pending CN113226283A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862741295P 2018-10-04 2018-10-04
US62/741,295 2018-10-04
PCT/US2019/053808 WO2020072357A1 (en) 2018-10-04 2019-09-30 Improvement of glymphatic delivery by manipulating plasma osmolarity

Publications (1)

Publication Number Publication Date
CN113226283A true CN113226283A (zh) 2021-08-06

Family

ID=68502006

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980075683.8A Pending CN113226283A (zh) 2018-10-04 2019-09-30 通过操纵血浆重量摩尔渗透压浓度改善淋巴递送

Country Status (8)

Country Link
US (1) US12311035B2 (https=)
EP (1) EP3860564A1 (https=)
JP (2) JP7611149B2 (https=)
KR (1) KR20210100086A (https=)
CN (1) CN113226283A (https=)
AU (1) AU2019354965B2 (https=)
CA (1) CA3115071A1 (https=)
WO (1) WO2020072357A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023538831A (ja) * 2020-08-03 2023-09-12 トランスルミナル、システムズ、リミテッド、ライアビリティー、カンパニー 病理組織の経動脈浸透圧塞栓形成のためのデバイスおよび方法
WO2023073526A1 (en) * 2021-10-25 2023-05-04 Novartis Ag Methods for improving adeno-associated virus (aav) delivery
JP2026510233A (ja) 2023-02-16 2026-04-02 ユニバーシティー オブ ロチェスター グリンパ－リンパ流出の改善
US12483569B2 (en) 2024-03-28 2025-11-25 Bank Of America Corporation System and method for identifying unauthorized data traffic in a computing network
WO2025250454A1 (en) * 2024-05-28 2025-12-04 University Of Rochester Adeno-associated viruses evolved to specifically target human glial progenitor cells in vivo

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080267952A1 (en) * 2004-07-19 2008-10-30 Robert Moir Antibodies to Cross-Linked Beta-Amyloid Protein Oligomers
CN105228652A (zh) * 2013-02-21 2016-01-06 罗契斯特大学 评价全脑血管旁路径的废弃物清除功能的方法以及基于这种方法治疗神经退化性病症的方法
US20170105927A1 (en) * 2015-10-15 2017-04-20 Wisconsin Alumni Research Foundation Osmotic enhancement of drug/therapeutic delivery to the brain following infusion or injection into the cerebrospinal fluid
WO2018015467A1 (en) * 2016-07-20 2018-01-25 P&X Medical Nv Compounds for use in methods for treating glaucoma and retinal diseases

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5869248A (en) 1994-03-07 1999-02-09 Yale University Targeted cleavage of RNA using ribonuclease P targeting and cleavage sequences
US5599706A (en) 1994-09-23 1997-02-04 Stinchcomb; Dan T. Ribozymes targeted to apo(a) mRNA
US6083702A (en) 1995-12-15 2000-07-04 Intronn Holdings Llc Methods and compositions for use in spliceosome mediated RNA trans-splicing
ATE354957T1 (de) 1995-12-15 2006-03-15 Intronn Inc Durch trans-spaltung erhaltene therapeutische molekule
DE1257584T1 (de) 2000-02-24 2003-05-28 Lilly Co Eli Humanisierte antikörper, die amyloid beta peptid demarkieren
CA2441903C (en) 2000-05-26 2012-07-31 National Research Council Of Canada Single-domain brain-targeting antibody fragments derived from llama antibodies
CA2414772C (en) 2000-07-07 2011-06-28 Jan Naslund Prevention and treatment of alzheimer's disease
PE20020574A1 (es) 2000-12-06 2002-07-02 Wyeth Corp Anticuerpos humanizados que reconocen el peptido amiloideo beta
WO2003016467A2 (en) 2001-08-17 2003-02-27 Eli Lilly And Company Use of antibodies having high affinity for soluble ass to treat conditions and diseases related to ass
CA2451998A1 (en) 2001-08-17 2003-02-27 Eli Lilly And Company Anti-a.beta. antibodies
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
WO2004029629A1 (en) 2002-09-27 2004-04-08 Janssen Pharmaceutica N.V. N-11 truncated amyloid-beta nomoclonal antibodies, compositions, methods and uses
US20040146512A1 (en) 2002-10-09 2004-07-29 Arnon Rosenthal Methods of treating Alzheimer's disease using antibodies directed against amyloid beta peptide and compositions thereof
US20050142141A1 (en) 2002-11-27 2005-06-30 Pardridge William M. Delivery of enzymes to the brain
EA200501524A1 (ru) 2003-03-28 2006-06-30 Сентокор, Инк. Антитела против амилоида, композиции, способы и применения
TWI306458B (en) 2003-05-30 2009-02-21 Elan Pharma Int Ltd Humanized antibodies that recognize beta amyloid peptide
US8801541B2 (en) 2007-09-27 2014-08-12 Taylor Made Golf Company, Inc. Golf club
MX2007000998A (es) 2004-07-30 2007-07-11 Rinat Neuroscience Corp Anticuerpos dirigidos peptido beta-amiloide y procedimientos que usan los mismos.
WO2006039470A2 (en) 2004-09-29 2006-04-13 Centocor, Inc. Anti- amyloid antibodies, compositions, methods and uses
CA2589017A1 (en) 2004-12-15 2006-06-22 Neuralab Limited Amyloid beta antibodies for use in improving cognition
EP1838348B1 (en) 2004-12-15 2013-06-26 Janssen Alzheimer Immunotherapy Humanized amyloid beta antibodies for use in improving cognition
US7625560B2 (en) 2004-12-15 2009-12-01 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
ES2259270B1 (es) 2005-03-09 2007-11-01 Consejo Superior De Investigaciones Cientificas Metodo de diagnostico in vitro de la enfermedad de alzheimer mediante un anticuerpo monoclonal.
WO2009027105A2 (en) 2007-08-31 2009-03-05 Neurimmune Therapeutics Ag Method of providing patient specific immune response in amyloidoses and protein aggregation disorders
EP3000481A3 (en) 2009-07-14 2016-05-11 Mayo Foundation for Medical Education and Research Peptide-mediated non-covalent delivery of active agent agents across the blood brain barrier
US9676849B2 (en) 2012-01-10 2017-06-13 Biogen Ma Inc. Enhancement of transport of therapeutic molecules across the blood brain barrier
US10508151B2 (en) 2014-11-19 2019-12-17 Genentech, Inc. Anti-transferrin receptor antibodies and methods of use
US10907176B2 (en) 2015-01-14 2021-02-02 The University Of North Carolina At Chapel Hill Methods and compositions for targeted gene transfer
US10632080B2 (en) 2015-09-11 2020-04-28 The Johns Hopkins University Compositions and methods to improve nanoparticle distribution within the brain interstitium
WO2017123757A1 (en) * 2016-01-15 2017-07-20 Sangamo Therapeutics, Inc. Methods and compositions for the treatment of neurologic disease
WO2017210343A1 (en) * 2016-06-01 2017-12-07 The University Of Virginia Patent Foundation Methods and compositions for modulating lymphatic vessels in the central nervous system
US10457717B2 (en) 2017-02-17 2019-10-29 Denali Therapeutics Inc. Engineered polypeptides

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080267952A1 (en) * 2004-07-19 2008-10-30 Robert Moir Antibodies to Cross-Linked Beta-Amyloid Protein Oligomers
CN105228652A (zh) * 2013-02-21 2016-01-06 罗契斯特大学 评价全脑血管旁路径的废弃物清除功能的方法以及基于这种方法治疗神经退化性病症的方法
US20170105927A1 (en) * 2015-10-15 2017-04-20 Wisconsin Alumni Research Foundation Osmotic enhancement of drug/therapeutic delivery to the brain following infusion or injection into the cerebrospinal fluid
WO2018015467A1 (en) * 2016-07-20 2018-01-25 P&X Medical Nv Compounds for use in methods for treating glaucoma and retinal diseases

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BENJAMIN A. PLOG等: "The glymphatic system in CNS health and disease: past, present and future", ANNU REV PATHOL., vol. 13, no. 1, pages 379 - 394, XP055664057, DOI: 10.1146/annurev-pathol-051217-111018 *
ZAIM WADGHIRI等: "Detection of Alzheimer’s Amyloid in Transgenic Mice Using Magnetic Resonance Microimaging", MAGNETIC RESONANCE IN MEDICINE, vol. 50 *

Also Published As

Publication number Publication date
US20220031867A1 (en) 2022-02-03
JP7611149B2 (ja) 2025-01-09
CA3115071A1 (en) 2020-04-09
EP3860564A1 (en) 2021-08-11
WO2020072357A1 (en) 2020-04-09
AU2019354965B2 (en) 2025-03-27
US12311035B2 (en) 2025-05-27
JP2024099600A (ja) 2024-07-25
JP2022508609A (ja) 2022-01-19
KR20210100086A (ko) 2021-08-13
AU2019354965A1 (en) 2021-05-06

Similar Documents

Publication Publication Date Title
JP7611149B2 (ja) 血漿浸透圧を操作することによるグリンパティック送達の改善
Liu et al. Secreted protein acidic and rich in cysteine mediated biomimetic delivery of methotrexate by albumin-based nanomedicines for rheumatoid arthritis therapy
Plog et al. Transcranial optical imaging reveals a pathway for optimizing the delivery of immunotherapeutics to the brain
Kress et al. Impairment of paravascular clearance pathways in the aging brain
Li et al. Mechanisms of enhanced antiglioma efficacy of polysorbate 80‐modified paclitaxel‐loaded PLGA nanoparticles by focused ultrasound
Theek et al. Sonoporation enhances liposome accumulation and penetration in tumors with low EPR
Waggoner et al. Porous silicon nanoparticles targeted to the extracellular matrix for therapeutic protein delivery in traumatic brain injury
Hong et al. Chitosan-based multifunctional platforms for local delivery of therapeutics
He et al. High-density lipoprotein nanoparticles spontaneously target to damaged renal tubules and alleviate renal fibrosis by remodeling the fibrotic niches
Wang et al. Drug delivery pathways to the central nervous system via the brain glymphatic system circumventing the blood‐brain barrier
Zhou et al. ROS/electro dual-reactive nanogel for targeting epileptic foci to remodel aberrant circuits and inflammatory microenvironment
US20220280423A1 (en) Glymphatic delivery by manipulating plasma osmolarity
Han et al. The emerging role of exosomes in communication between the periphery and the central nervous system
KR20180035209A (ko) 종양에 대한 활성제의 더 나은 전달 방법
Liu et al. Reactive oxygen species-responsive sequentially targeted AIE fluorescent probe for precisely identifying the atherosclerotic plaques
Zong et al. Intra-articular injection of PLGA/Polydopamine core–shell nanoparticle attenuates osteoarthritis progression
Saveleva et al. Mucoadhesive emulsion microgels for intravesical drug delivery: preparation, retention at urothelium, and biodistribution study
Peng et al. Nanomaterials: recent advances in knee osteoarthritis treatment
Zheng et al. A pH-induced reversible assembly system with resveratrol-controllable loading and release for enhanced tumor-targeting chemotherapy
Shi et al. Advances in nanotherapy for targeting senescent cells
Nagri et al. Nanomedicine strategies for central nervous system (CNS) diseases
Sun et al. Exploring the interstitial system in the brain: the last mile of drug delivery
Grimm et al. Nanotechnology Approaches to Targeting Inflammation and Excitotoxicity in a Canine Model of Hypothermic Circulatory Arrest–Induced Brain Injury
Xavierselvan et al. Oxygen-releasing nanodroplets relieve intratumoral hypoxia and potentiate photodynamic therapy in 3D head and neck cancer spheroids
Hunt Precision targeting of intraperitoneal tumors with peptideguided nanocarriers

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40058950

Country of ref document: HK